Reports Q2 revenue $8.51M, consensus $7.72M. The company ended the quarter with $205.M in cash, cash equivalents, and marketable securities, which it anticipates will support operations into 2027. Based on current information, the company plans to submit an investigational new drug and clinical trial application for its MGX-001 Hemophilia A program in 2026. “Entering the second half of the year, we continue to advance our MGX-001 wholly-owned program for hemophilia A towards pre-IND and ex-U.S. regulatory meetings in 2025, and our collaboration with Ionis in cardiometabolic indications towards nomination of development candidates in 2025,” said Brian Thomas, PhD, CEO and founder of Metagenomi (MGX). “Our strong balance sheet and continued focus on operational efficiency are enabling investment in both our pipeline and AI-driven metagenomics platform.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX: